Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Phase 2

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Bendamustine
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2014-07-11

Last Posted Date: 2019-06-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 163

Registration Number: NCT02187861

Locations: 🇦🇺
Royal Prince Alfred Hospital; Medical Oncology, Camperdown, New South Wales, Australia
🇧🇪
Cliniques Universitaires St-Luc, Bruxelles, Belgium
🇧🇪
ZNA Stuivenberg, Antwerpen, Belgium

and more 68 locations

Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Lymphoma, Non-Hodgkin

Interventions: Drug: Carfilzomib
Drug: Bendamustine
Drug: Rituximab

First Posted Date: 2014-07-10

Last Posted Date: 2021-04-23

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 10

Registration Number: NCT02187133

Locations: 🇺🇸
University of California, San Diego, San Diego, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
University of California, Davis, Davis, California, United States

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1

Terminated

Conditions: B-cell Adult Acute Lymphoblastic Leukemia
B-cell Chronic Lymphocytic Leukemia
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Adult Grade III Lymphomatoid Granulomatosis
Recurrent Mycosis Fungoides/Sezary Syndrome
Intraocular Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride
Biological: rituximab
Other: laboratory biomarker analysis

First Posted Date: 2014-06-20

Last Posted Date: 2018-07-02

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 1

Registration Number: NCT02168907

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Adult Lymphocyte Predominant Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Hepatosplenic T-cell Lymphoma
T-cell Large Granular Lymphocyte Leukemia
Adult Nasal Type Extranodal NK/T-cell Lymphoma
T-cell Adult Acute Lymphoblastic Leukemia
Noncutaneous Extranodal Lymphoma
Recurrent Adult T-cell Leukemia/Lymphoma
Adult Mixed Cellularity Hodgkin Lymphoma
Adult Nodular Sclerosis Hodgkin Lymphoma

Interventions: Drug: 6,8-bis(benzylthio)octanoic acid
Drug: bendamustine hydrochloride

First Posted Date: 2014-06-20

Last Posted Date: 2024-02-13

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 16

Registration Number: NCT02168140

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

Phase 1

Active, not recruiting

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
Post-Transplant Lymphoproliferative Disorder
B-Cell Prolymphocytic Leukemia
High Grade B-Cell Lymphoma, Not Otherwise Specified
Recurrent Adult Burkitt Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Hairy Cell Leukemia
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Recurrent Lymphoplasmacytic Lymphoma

Interventions: Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Drug: Bendamustine Hydrochloride
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Fludarabine Phosphate

First Posted Date: 2014-06-03

Last Posted Date: 2024-01-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 37

Registration Number: NCT02153580

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Neuroblastoma
Lymphoma
High-risk Tumor

Interventions: Biological: CD133+ selected autologous stem cell infusion
Biological: IL-2
Biological: hu14.18K322A
Drug: Melphalan
Drug: Busulfan
Drug: Bendamustine
Biological: GM-CSF
Drug: Etoposide
Drug: Carboplatin
Device: Haploidentical natural killer cell infusion
Drug: Cytarabine
Biological: G-CSF
Device: CliniMACS
Drug: Etoposide phosphate

First Posted Date: 2014-05-06

Last Posted Date: 2017-12-22

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 8

Registration Number: NCT02130869

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Bendamustine Hydrochloride
Drug: Carfilzomib
Drug: Dexamethasone
Other: Laboratory Biomarker Analysis

First Posted Date: 2014-03-26

Last Posted Date: 2021-01-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT02095834

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: bendamustine
Drug: obinutuzumab

First Posted Date: 2014-02-25

Last Posted Date: 2020-02-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 72

Registration Number: NCT02071225

Locations: 🇪🇸
Hospital General Universitario de Elche; Servicio de Hematologia, Elche, Alicante, Spain
🇪🇸
Hospital de Cabueñes; Servicio de Hematología y Hemoterapia, Gijon, Asturias, Spain
🇪🇸
Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain

and more 18 locations

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Carmustine
Drug: Etoposide
Drug: Melphalan
Drug: Cytarabine
Drug: Alemtuzumab
Biological: Autologous Stem Cell Transplantation
Biological: Allogeneic Stem Cell Transplantation
Drug: Rituximab

First Posted Date: 2014-02-11

Last Posted Date: 2021-02-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 34

Registration Number: NCT02059239

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 3

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Bendamustine
Drug: Venetoclax
Drug: Rituximab

First Posted Date: 2013-12-09

Last Posted Date: 2023-10-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 389

Registration Number: NCT02005471

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc; Hematology, Bruxelles, Belgium
🇺🇸
Huntsman Cancer Institute; University of Utah, Salt Lake City, Utah, United States
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 108 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy